Markets open

argenx SE American Depositary Shares

ARGX · NASDAQ-GS

Sep 2026upcoming

Next quarter

Consensus is $7.18 EPS for Sep 2026 across 7 estimates, ranging $6.39 to $8.75.

ARGX Jun 2026

Reported Jul 23, 2026

Beat 19.41%

EPS estimate: $6.13
EPS actual: $7.32
Revenue estimate: —
Revenue actual: —
1-day move: -0.69%

Call highlights have not been generated for this quarter.

Symbol: ARGX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: Europe
Exchange: NASDAQ-GS

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.